The FDA has approved talimogene laherparepvec, or T-VEC, to treat surgically unresectable skin and lymph node lesions in patients with advanced melanoma. T-VEC is the first oncolytic viral therapy to gain regulatory endorsement, based on data from the OPTiM study.
The FDA has approved talimogene laherparepvec (Imlygic; Amgen) to treat surgically unresectable skin and lymph node lesions in patients with advanced melanoma. Also called T-VEC, this is the first oncolytic virus to gain regulatory endorsement.
T-VEC, a genetically modified herpes simplex virus type 1, is thought to have two distinct means of antitumor activity: Its selective replication in cancer cells causes them to rupture and die; meanwhile, it also releases the cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF), which spurs the patient's own immune system into tumor-fighting mode. However, Amgen has stated that T-VEC's “exact mechanism of action is unknown and being further investigated.”
T-VEC's approval was based on data from the multicenter phase III OPTiM study, in which 436 patients with surgically unresectable metastatic melanoma were randomized to receive injections of T-VEC directly into their lesions, or GM-CSF given subcutaneously (J Clin Oncol 2015;33:2780–8). Among patients in the T-VEC arm, 16.3% achieved durable responses—tumor shrinkage lasting at least 6 months—compared with 2.1% in the control group. The median overall survival with T-VEC was 23.3 months, versus 18.9 months with GM-CSF, which was not statistically significant, prompting the FDA and Amgen to emphasize that T-VEC “has not been shown to improve overall survival.” The therapy also had no effect on melanoma that had spread to other internal organs.
T-VEC was well tolerated by patients, with the most common side effects being fatigue, chills, and fever. Given the live nature of this therapy, cold sores and other herpetic infections were also observed.
According to preliminary data from a small phase I study, T-VEC plus the immune checkpoint inhibitor ipilimumab (Yervoy; Bristol-Myers Squibb) may also show promise in melanoma: Half of the study's 19 patients responded, 22% completely. In addition, T-VEC is being evaluated alongside another checkpoint inhibitor, pembrolizumab (Keytruda; Merck), which blocks interactions between the ligand PD-L1 and its receptor, PD-1. A recent review noted that “as oncolytic viruses often induce interferon release in the local tumor microenvironment, and interferon is known to upregulate PD-L1 expression on tumor cells, this combination is especially interesting” (Nat Rev Drug Discov 2015;14:642–62).
Marc Ernstoff, MD, director of the melanoma program at Cleveland Clinic's Taussig Cancer Institute in Ohio, notes that T-VEC has only “modest single-agent activity,” and “its place in the growing immunotherapy armamentarium is still unclear.” He adds, though, that “its unique mechanism of immune stimulation and high therapeutic index provide significant opportunities for multiagent regimens that can further leverage the immune path to durable tumor destruction.”
“It's worth noting that we had only three approved agents for melanoma in the 30 years before 2011,” says John Kirkwood, MD, director of the melanoma skin and cancer program at the University of Pittsburgh, PA. T-VEC is the 10th new therapy approved for melanoma in the last 5 years, which the Melanoma Research Alliance has hailed as “a truly unprecedented rate of progress.” –Alissa Poh
For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.